Sarepta guides Q4 sales below estimates
Source: SeekingAlpha
2026-01-12 12:42:52 ET
More on Sarepta Therapeutics
- Sarepta Therapeutics: Why The Newborn Screening Decision For DMD Matters More Than The Stock Move Suggests
- Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026
- FDA Duchenne Failure Hits Sarepta Amid 3Q25 Earnings Beat
- Sarepta rises as HHS adds Duchenne muscular dystrophy to newborn screenings
- Sarepta to refinance $291M of existing notes due 2027
Read the full article on Seeking Alpha
For further details see:
Sarepta guides Q4 sales below estimates
Sarepta Therapeutics Inc.
NASDAQ: SRPT
SRPT Trading
-1.15% G/L:
$16.9675 Last:
1,018,094 Volume:
$17.445 Open:
SRPT Latest News
February 27, 2026 09:00:00 am
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
SRPT Stock Data
$1,921,797,010
96,823,361
N/A
132
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
